Development of a vaccine for genital chlamydial infection

Funding Activity

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Genital Chlamydia infections are the most common sexually transmitted infection in Australia with annual health costs of 90-160 million dollars. Infection rates in 15-29 olds are increasing at 15-20% per year. Antibiotics are currently the treatment of choice, however antibiotic resistance is increasing and most infections are asymptomatic and not treated in the absence of screening programs. This project aims to develop a genital Chlamydia vaccine using a combination of novel antigens.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2009

Funding Scheme: NHMRC Development Grants

Funding Amount: $207,551.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Chlamydia | Infectious Disease | Infertility | Mucosal Immunity | Mucosal Vaccines | Pelvic inflammatory disesse | Reproductive Health | Sexually Transmitted Disease | Vaccine development